同仁堂科技(01666.HK)年度淨利潤預降35%-40%
格隆匯2月28日丨同仁堂科技(01666.HK)公佈,董事會預計2019年度集團歸屬於母公司所有者的淨利潤較上年同期將下降35%-40%。
業績預計下降主要由於,隨着工業佈局調整的進一步深入,公司進入新舊產能銜接的過渡期,加之受現有生產單位進行GMP(藥品生產質量管理規範)再認證工作等因素影響,公司整體面臨着原有產能不足、新產能未釋放等問題,而工業單位生產產能不足,產品產量、產值下降,直接導致了銷售量的下降,從而對集團銷售收入和利潤產生影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.